TACE

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCPCS, Interest, Second Half, Patient, APC, Sale, Society, University, Bank statement, Investment, Therapy, Marketing, DCR, Webcast, Hepatocellular carcinoma, CMS, Abdominal ultrasonography, Vein, Disease, Opinion, Immunotherapy, Safety, Manuscript, Cholangiocarcinoma, Pancreas, PFS, FDA, Liver disease, HCC, OS, Uveal melanoma, MDSC, Growth, TACE, Commander, U.S. Pacific Fleet, Drug, MD Anderson Cancer Center, Data, Medicare, Liver, Pharmaceutical industry

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • This new code, HCPCS 9797, has been assigned to the Ambulatory Payment Classification (APC) 5194 – Level 4 Endovascular Procedures.
  • The Company is working diligently to evaluate the materiality of the errors to determine whether any corrections for the third quarter financial results are required and to complete the Company’s year-end 2023 financial statements.
  • Operating losses were $14.1 million and $54.2 million, respectively, for the fourth quarter and full year ended December 31, 2023.

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Pharmaceutical, Surgery, Oncology, Health, FDA, Medical Devices, Clinical Trials, Liver, FACS, Neoplasm, Blood, CMS, Immunotherapy, Liver disease, Hepatocellular carcinoma, Liver cancer, Manuscript, TACE, Data, Medicare, Patient, HCPCS, Disease, Clutch (eggs), HCC, Medical imaging

Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.

Key Points: 
  • Key findings include that TriNav patients, despite a higher baseline disease burden and clinical complexity, showed overall clinical results comparable to patients with lower disease burden.
  • In a matched cohort comparison, TriNav patients had fewer 30-day inpatient visits post-procedure than non-TriNav patients.
  • TriNav TARE patients with liver metastases had fewer clinical complications post-procedure vs. non-TriNav patients in a matched cohort comparison.
  • “This large sample size study underscores the particular benefits of the TriNav device compared to standard drug delivery systems.”

VinBrain to Launch AI-centric Solutions to Save Lives and Advance Precision Care at RSNA 2023

Retrieved on: 
Monday, December 4, 2023
Cloud, Liver, Radiology, Microsoft Band, Life expectancy, Stanford University, Cancer, Vingroup, Diagnosis, Microsoft, Hepatocellular carcinoma, Artificial intelligence, SOTA, EDS, Privacy, Exhibition, Knowledge, Fellow, Azure, Health care, Scientific Reports, Medical imaging, Physician, Tuberculosis, HCC, CXR, AI, TACE, HIPAA, Patient, Medicine, NVIDIA, TB, TME, HIS, Learning, Research, R&D, RIS, PACS, EMR, NIST, Health, Graphics processing unit, RSNA, Medical device

Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.

Key Points: 
  • Unveiling two impactful AI-centric solutions during the event - DrAid Enterprise Data Solution: Centralization, Transformation, Intelligence; and DrAid Oncology Diagnosis and Treatment, VinBrain takes major steps forward in innovation, aiming to save more lives and advance precision care for everyone.
  • Expediting interoperability and streamlining, DrAid Enterprise Data Solution (EDS) is hoped to lead the healthcare transformation towards precision care.
  • Dr. Michael C. Muelly, medical partner of VinBrain shared his point of view about clinical practices and values of the solutions during product launch at RSNA 2023.
  • At RSNA 2023, VinBrain also showcased its commitment to providing accessible healthcare in underserved regions with high tuberculosis burden through DrAid for Tuberculosis Screening (CXR Screening).

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

Retrieved on: 
Thursday, June 8, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Gastrointestinal cancer, AACR, Lenvatinib, TACE, Cholangiocarcinoma, MRK, American Association for Cancer Research, Cisplatin, Merck & Co., Eisai, Patient, Annual general meeting, PDUFA, BTC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, HCC, Food, Pharmaceutical industry, Merck

The sBLA is based on data from the KEYNOTE-966 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) compared to chemotherapy alone.

Key Points: 
  • The sBLA is based on data from the KEYNOTE-966 trial, in which KEYTRUDA plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS) compared to chemotherapy alone.
  • Results from KEYNOTE-966 were presented at the American Association for Cancer Research (AACR) 2023 Annual Meeting.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of February 7, 2024.
  • “Most biliary tract cancers go undetected until an advanced stage, at which point many patients are ineligible for surgery and have few treatment options,” said Dr. Scot Ebbinghaus, vice president, global clinical development, Merck Research Laboratories.

Global Embolotherapy Market Analysis/Forecasts, 2022-2023 & 2029 - Growing Patient Population With Chronic Conditions Increasing the Demand for Embolization Procedures - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 1, 2023
Health, Other Health, Hospital, Moyamoya disease, TACE, Urology, Microparticle, PVA, Transcatheter arterial chemoembolization, Neurology, TAE, Gelatin, Liver cancer, Arteriovenous malformation, Brachytherapy, Growth, Lung cancer, SIRT, Prevalence, Intracranial aneurysm, AVM, Video game, Speciality chemicals, Pharmaceutical industry, Nursing, Selective internal radiation therapy

The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.

Key Points: 
  • The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029.
  • The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029.
  • Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.
  • The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares.

Interventional Oncology Global Market - Forecast To 2029

Retrieved on: 
Thursday, December 22, 2022
Liver cancer, Johnson & Johnson, Radiofrequency ablation, Patient, Brain, LATAM, Liver, Interventional oncology, Kidney cancer, ASC, Medtronic, Boston Scientific, Kidney, SIRT, TACE, Lung cancer, Asia-Pacific Telecommunity band plan in the 700 MHz band, Prevalence, Electroporation, Therapy, Cancer, TAE, Prostate, Lung, IO, Geography, Incidence, Hospital, Prostate cancer, Medical imaging, Varian, Cryoablation

View original content:https://www.prnewswire.com/news-releases/interventional-oncology-global-...

Key Points: 
  • According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029.
  • Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others.
  • The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes.
  • The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares.

Interventional Oncology Market - Global Forecast to 2026 - Expansion in the Emerging Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 29, 2022
Health, Oncology, Incidence, Liver cancer, Radiofrequency ablation, Brain, Prevalence, Geography, Hospital, ASC, TACE, Asia-Pacific Telecommunity band plan in the 700 MHz band, Kidney cancer, Lung cancer, Cancer, Electroporation, SIRT, Therapy, Prostate cancer, TAE, Medicine, Medical imaging, Cryoablation

The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The interventional oncology global market is expected to grow at a high single from 2022 to 2029.
  • Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market.
  • Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others.

New Embolic Device Demonstrates Superior Vessel Filling in Tumor Models

Retrieved on: 
Wednesday, August 10, 2022
Multimedia, DMSO, Polymerization, Embolus, Metal, Neoplasm, Technology, Aneurysm, Embolization, Birth, Bleeding, TACE, GPX, DVM, University of Utah, University, SALT, Microparticle, Blood, Bed, Medical imaging, Medical device

SALT LAKE CITY, Aug. 10, 2022 /PRNewswire/ -- Fluidx Medical disclosed study results examining extent of vessel filling using the GPX Embolic Device compared to microspheres, a common treatment for many types of tumors. 

Key Points: 
  • "The ability to fill the smallest tumor feeding vessels and reach distal vessel beds is very important in effective treatment of hypervascular tumors and in other therapeutic embolic procedures."
  • The GPX Embolic Device was found to fill vessels more completely and penetrate deeper into smaller vessel beds than the smallest microspheres commonly used for tumor treatments.
  • About the GPX Embolic Device:
    The GPX Embolic Device is an innovative embolic designed for simple preparation and controllable material delivery.
  • The GPX Embolic Device is under development and does not have marketing clearance or approval in any market at this time.

Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer

Retrieved on: 
Tuesday, June 21, 2022
Doctor of Philosophy, TACE, Tirapazamine, Fever, FDA, Therapy, Journal, HCC, Safety, B cell, BCLC, Radiofrequency ablation, CEO, Liver, Survival, Tumor necrosis factor, Recurrence, Liver cancer, TATE, MD, GLOBE, Immunotherapy, Doxorubicin, Journal of Vascular and Interventional Radiology, Hepatocellular carcinoma, Patient, Abdominal pain, Neoplasm, Necrosis, ECG, Interventional radiology, TPZ, Medical imaging, Pharmaceutical industry

PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled “Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma,” establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).

Key Points: 
  • The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin.
  • The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization.
  • Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study.
  • A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.

Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Monday, January 17, 2022
MSD, American Society of Clinical Oncology, Patient, Research, RNA, Safety, Knowledge, TACE, Pembrolizumab, 2021 Essex County Council election, Society, LEAP, Merck, Merck Sharp & Dohme Federal Credit Union, Cancer, Abstract, Tumor microenvironment, Merck & Co., Team Impulse, Eisai, ASCO, Phase, FDA, Trial of the century, Pharmaceutical industry

TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.

Key Points: 
  • TOKYO, Jan 17, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.